The Negotiation Happening in Every Cell: NAD+ and the Art of Triage

There is a reason the body never simply runs out of a single thing. Biology is less like a machine with discrete parts and more like an economy — full of trade-offs, competing demands, and constant negotiation between what is needed now and what can wait. NAD+, or nicotinamide adenine dinucleotide, sits near the center of that negotiation. And the more researchers study it, the more it looks less like a simple energy carrier and more like a triage coordinator — one whose influence over what the body prioritizes may have profound implications for how we age.

What Triage Actually Means at the Cellular Level

Most introductions to NAD+ begin with mitochondria and energy production, which is accurate but incomplete. What tends to get less attention is the allocation problem: when cellular resources are limited, who gets served first?

NAD+ is consumed not only in energy metabolism but by a class of enzymes called sirtuins — proteins closely associated with DNA repair, inflammation regulation, and stress response — as well as by PARP enzymes, which mobilize rapidly whenever DNA sustains damage. The body's instinct, quite sensibly, is to patch injuries before doing anything else. When you encounter oxidative stress, infection, or environmental insult, PARP enzymes draw heavily on NAD+ reserves. That's the right call in the short term. The problem is what happens when the insults are chronic and the reserves are thin.

Research suggests that NAD+ levels decline substantially with age — some estimates place the drop at roughly 50 percent between early adulthood and midlife. When that happens, the triage hierarchy becomes strained. Repair processes that once ran quietly in the background now compete with basic energy metabolism. Sirtuins, which appear to require robust NAD+ availability to function properly, may become less active. The cell is still working. It's just working with less margin, less flexibility, and less capacity to recover cleanly from each day's accumulated stress.

"The cell does not stop functioning when NAD+ declines — it simply stops functioning well."

The Rhythm of Resource and Repair

One of the more interesting threads in recent NAD+ research involves circadian biology — the internal timing systems that coordinate when the body repairs, regenerates, and restores. Cellular processes don't run at a flat rate across the day; they are scheduled, in ways that evolution has refined over millions of years. Repair tends to happen at rest. Synthesis tends to happen during activity. The timing is not incidental — it appears to be deeply linked to NAD+ availability and its role in activating the very enzymes that keep cellular clocks running on schedule.

A recent narrative review (Nakajima & Koibuchi, 2026) examined NAD+ in the context of healthy ageing broadly, noting its intersecting roles in metabolic regulation, stress resilience, and what researchers increasingly describe as the coherence of cellular function over time. That phrase — coherence of cellular function — is worth sitting with. It suggests that what we experience as vitality may not just be about how much energy a cell can generate, but about how well-coordinated the entire system remains across competing demands and across time.

When NAD+ levels fall, that coordination may become noisier. Not broken — just less precise. The signals that tell cells when to repair and when to rebuild and when to rest become harder to read cleanly. Over years, that loss of precision is thought to be one of the underlying drivers of the fatigue, cognitive softness, and slower recovery that many people experience as they move through their forties and fifties, attributing it simply to "getting older" when it may, in part, reflect a resolvable resource shortage.

Replenishment as a Biological Argument

The case for addressing NAD+ decline isn't built on the idea that aging is a disease to be defeated. It's built on something more measured: that some of what we attribute to the passage of time is actually the downstream effect of a system running on depleted inputs. Restore the input, and some of the downstream effects may shift accordingly.

Intravenous NAD+ delivery has attracted particular interest because it bypasses the digestive process entirely, allowing concentrations to reach the bloodstream — and, researchers hope, the tissues — more directly than oral supplementation can reliably achieve. The clinical literature is still developing, and the honest answer is that the full picture of what replenishment does, over what timeframe, and for whom, is not yet complete. What research does suggest is that the molecule is foundational enough, and its decline consistent enough, that the question of how to address it is a serious one worth taking seriously.

What stays with me is the elegance of the triage model. The body isn't failing when NAD+ declines — it's making the best decisions it can with what it has. Giving it more to work with isn't a workaround. It's an attempt to restore the conditions under which the body's own intelligence can do what it was always designed to do.